Hollis-Eden says several drug candidates show anti-disease compounds

By Lisa Kerner

Charlotte, N.C., Sept. 12 - Hollis-Eden Pharmaceuticals, Inc. said preclinical data showed the potential therapeutic benefits of its second-generation drug candidates derived from its hormonal signaling technology platform.

The company said HE3204 and HE3286 demonstrated anti-inflammatory activity, HE3286 also demonstrated benefits in an animal model of diabetes and HE3235 can inhibit adrenal steroid-induced tumors.

Several of Hollis-Eden's second-generation compounds regulate the protein NF-kappaB, which plays a role in cellular signaling.

The company said this data validates its core scientific hypothesis that this class of compounds plays a key role in restoring or inhibiting signals that regulate host response to disease.

Hollis-Eden is a San Diego-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.